|
1.
|
|
10 p, 768.8 KB |
BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis : the prospective MABOMET GEICAM study
/
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Muñoz, M. (Hospital Clínic i Provincial de Barcelona) ;
Margelí, M. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Chacón, J.I. (Hospital Virgen de la Salud) ;
Cassinello, J. (Hospital General de Guadalajara) ;
Antolin, S. (Complejo Hospitalario U. A Coruña) ;
Adrover, E. (Complejo Hospitalario Universitario de Albacete) ;
Ramos, M. (Centro Oncológico de Galicia) ;
Carrasco, E. (GEICAM (Spanish Breast Cancer Group)) ;
Jimeno, M.A. (GEICAM (Spanish Breast Cancer Group)) ;
Ojeda, B. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
González, X. (Hospital General de Catalunya) ;
González, S. (Hospital Mutua de Terrassa. Barcelona) ;
Constenla, M. (Complejo Hospitalario De Pontevedra) ;
Florián, J. (Hospital Comarcal de Barbastro) ;
Miguel, A. (Hospital Althaia Manresa) ;
Llombart, A. (Hospital Arnau de Vilanova) ;
Lluch, A. (Hospital Clínic Universitari de València) ;
Ruiz-Borrego, M. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Colomer, R. (Hospital Universitario La Princesa) ;
Del Barco, S. (Hospital Universitari de Girona Doctor Josep Trueta) ;
Universitat Autònoma de Barcelona
Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM. [...]
2019 -  10.1186/s41687-019-0161-y
Journal of Patient-Reported Outcomes, Vol. 3 Núm. 1 (january 2019) , p. 72
|
|
|
2.
|
|
12 p, 1.2 MB |
Adherence to breast cancer guidelines is associated with better survival outcomes : A systematic review and meta-analysis of observational studies in EU countries
/
Ricci-Cabello, I. (Ciber de Epidemiología y Salud Pública (CIBERESP)) ;
Vásquez-Mejía, A. (Universidad Nacional Mayor de San Marcos (Lima, Perú)) ;
Canelo Aybar, Carlos Gilberto (Institut d'Investigació Biomèdica Sant Pau) ;
Niño de Guzmán, Ena Pery (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Pérez-Bracchiglione, J. (Universidad de Valparaíso) ;
Rabassa Bonet, Montserrat (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Rigau, David (Institut d'Investigació Biomèdica Sant Pau) ;
Solà, Ivan (Institut d'Investigació Biomèdica Sant Pau) ;
Song, Yang (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Neamtiu, L. (Joint Research Centre (JRC)) ;
Parmelli, Elena (Joint Research Centre (JRC)) ;
Saz-Parkinson, Zuleika (Joint Research Centre (JRC)) ;
Alonso-Coello, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Breast cancer (BC) clinical guidelines offer evidence-based recommendations to improve quality of healthcare for patients with or at risk of BC. Suboptimal adherence to recommendations has the potential to negatively affect population health. [...]
2020 - 10.1186/s12913-020-05753-x
BMC health services research, Vol. 20 Núm. 1 (july 2020) , p. 920
|
|
|
3.
|
|
10 p, 1.1 MB |
Monitoring and evaluation of breast cancer screening programmes : Selecting candidate performance indicators
/
Muratov, S. (McMaster University (Canadà)) ;
Canelo Aybar, Carlos Gilberto (Institut d'Investigació Biomèdica Sant Pau) ;
Tarride, J.E. (McMaster University (Canadà)) ;
Alonso-Coello, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Dimitrova, N. (Joint Research Centre) ;
Borisch, B. (University of Geneva) ;
Castells, X. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Duffy, S.W. (Queen Mary University of London) ;
Fitzpatrick, P. (UCD School of Public Health) ;
Follmann, M. (German Cancer Society) ;
Giordano, L. (CPO-Piedmont - AOU Città della Salute e della Scienza) ;
Hofvind, S. (Cancer Registry of Norway) ;
Lebeau, A. (University Medical Center Hamburg-Eppendorf) ;
Quinn, C. (Elisabethinen Hospital) ;
Torresin, A. (ASST Grande Ospedale Metropolitano) ;
Vialli, C. (Joint Research Centre) ;
Siesling, S. (University of Twente) ;
Ponti, A. (CPO-Piedmont - AOU Città della Salute e della Scienza) ;
Giorgi Rossi, P. (AUSL Reggio Emilia. IRCCS) ;
Schünemann, H. (McMaster University (Canadà)) ;
Nyström, L. (Umeå University) ;
Broeders, Mireille (Radboud University Medical Center) ;
Autelitano, M. ;
Colzani, E. ;
Daneš, J. ;
Gräwingholt, A. ;
Ioannidou-Mouzaka, L. ;
Knox, S. ;
Langendam, M. ;
McGarrigle, H. ;
Pérez Gómez, E. ;
Van Engen, R. ;
Warman, S. ;
Young, K. ;
Van Landsveld-Verhoeven, C. ;
Lerda, D. ;
Saz-Parkinson, Z. ;
Parmelli, Elena ;
Janusch-Roi, A. ;
Universitat Autònoma de Barcelona
In the scope of the European Commission Initiative on Breast Cancer (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with breast cancer (BC) mortality. [...]
2020 - 10.1186/s12885-020-07289-z
BMC Cancer, Vol. 20 Núm. 1 (24 2020) , p. 795
|
|
|
4.
|
|
8 p, 823.8 KB |
SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)
/
González-Santiago, S. (Hospital Universitario San Pedro de Alcántara) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Aguirre, Elena (Hospital Quirónsalud) ;
Alés-Martínez, J.E. (Hospital Nuestra Señora de Sonsoles) ;
Andrés, R. (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Balmaña Gelpí, Judith (Hospital Universitari Vall d'Hebron) ;
Graña, B. (Complexo Hospitalario Universitario (CHUAC)) ;
Herrero, A. (Hospital Universitario Miguel Servet) ;
Llort, Gemma (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
González-del-Alba, A. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
the SEOM Hereditary Cancer Working Group ;
Universitat Autònoma de Barcelona
Mutations in BRCA1 and BRCA2 high penetrance genes account for most hereditary breast and ovarian cancer, although other new high-moderate penetrance genes included in multigene panels have increased the genetic diagnosis of hereditary breast and ovarian cancer families by 50%. [...]
2020 - 10.1007/s12094-019-02262-0
Clinical & Translational Oncology, Vol. 22 Núm. 2 (january 2020) , p. 193-200
|
|
|
5.
|
|
13 p, 2.1 MB |
Risk-of-bias assessment of the randomized clinical trials and systematic reviews on surgical treatments for breast cancer-related lymphedema : A mapping review
/
Al-Sakkaf, Ali M. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Bonfill, X. (Xavier) (Institut d'Investigació Biomèdica Sant Pau) ;
Ardiles-Ruesjas, Sofia (Institut d'Investigació Biomèdica Sant Pau) ;
Bendersky, Josefina (Institut d'Investigació Biomèdica Sant Pau) ;
Solà, Ivan (Institut d'Investigació Biomèdica Sant Pau) ;
Masia, J. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
Breast cancer treatment is the principal cause of lymphedema in the upper extremities. Breast cancer-related lymphedema (BCRL) treatments were previously based on conservative therapy; surgical treatments are alternative options that could be highly beneficial, especially for patients who are not responsive to conservative therapy. [...]
2023 - 10.1016/j.bjps.2023.05.002
Journal of Plastic, Reconstructive and Aesthetic Surgery, Vol. 84 (september 2023) , p. 134-146
|
|
|
6.
|
|
7 p, 537.4 KB |
Intraoperative irradiation in breast cancer : preliminary results in 80 patients as partial breast irradiation or anticipated boost prior to hypo-fractionated whole breast irradiation
/
Li, X. (Universitat Autònoma de Barcelona) ;
Sanz, Javier (Hospital del Mar (Barcelona, Catalunya)) ;
Argudo, Núria (Hospital del Mar (Barcelona, Catalunya)) ;
Vernet-Tomas, Maria (Hospital del Mar (Barcelona, Catalunya)) ;
Rodríguez, N. (Hospital del Mar (Barcelona, Catalunya)) ;
Torrent, L. (Hospital del Mar (Barcelona, Catalunya)) ;
Fernández-Velilla, E. (Hospital del Mar (Barcelona, Catalunya)) ;
Pera, O. (Hospital del Mar (Barcelona, Catalunya)) ;
Huang, Y. (Universitat Autònoma de Barcelona) ;
Nicolau, P. (Hospital del Mar (Barcelona, Catalunya)) ;
Jiménez, M. (Hospital del Mar (Barcelona, Catalunya)) ;
Segura, M. (Hospital del Mar (Barcelona, Catalunya)) ;
Algara, Manuel (Hospital del Mar (Barcelona, Catalunya))
To present the first results of intraoperative irradiation (IORT) in breast cancer with a low-energy photon system used as partial breast irradiation (PBI) or as an anticipated boost before whole breast hypo-fractionated irradiation (IORT + WBI), concerning tolerance, side effects, quality of life, and patient-reported outcomes. [...]
2021 - 10.1007/s12094-021-02728-0
Clinical & Translational Oncology, Vol. 24 (november 2021) , p. 829-835
|
|
|
7.
|
|
16 p, 1.3 MB |
The Intricate Interplay between Cancer Stem Cells and Oncogenic miRNAs in Breast Cancer Progression and Metastasis
/
Tsintarakis, Antonis (National Hellenic Research Foundation) ;
Papalouka, Chara (National Hellenic Research Foundation) ;
Kontarini, Christina (National Hellenic Research Foundation) ;
Zoumpourlis, Panagiotis (National Hellenic Research Foundation) ;
Karakostis, Konstantinos (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Adamaki, Maria (National Hellenic Research Foundation) ;
Zoumpourlis, Vassilis (National Hellenic Research Foundation)
Complex signaling interactions between cancer cells and their microenvironments drive the clonal selection of cancer cells. Opposing forces of antitumor and tumorigenic potential regulate the survival of the fittest clones, while key genetic and epigenetic alterations in healthy cells force them to transform, overcome cell senescence, and proliferate in an uncontrolled manner. [...]
2023 - 10.3390/life13061361
Life, Vol. 13 (june 2023)
|
|
|
8.
|
|
20 p, 4.1 MB |
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer
/
Palafox, Marta (Hospital Universitari Vall d'Hebron) ;
Monserrat, Laia (Hospital Universitari Vall d'Hebron) ;
Bellet Ezquerra, Meritxell (Hospital Universitari Vall d'Hebron) ;
Villacampa Javierre, Guillermo (Hospital Universitari Vall d'Hebron) ;
Gonzalez-Perez, Abel (Universitat Pompeu Fabra) ;
Oliveira, Mafalda (Hospital Universitari Vall d'Hebron) ;
Brasó-Maristany, Fara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ibrahimi, Nusaibah (University Paris-Saclay) ;
Kannan, Srinivasaraghavan (Bioinformatics Institute (A*STAR)) ;
Mina, Leonardo (Medica Scientia Innovation Research (MedSIR)) ;
Herrera-Abreu, Maria Teresa (The Breast Cancer Now Research Centre) ;
Òdena, Andreu (Hospital Universitari Vall d'Hebron) ;
Sánchez-Guixé, Mònica (Hospital Universitari Vall d'Hebron) ;
Capelán, Marta (Hospital Universitari Vall d'Hebron) ;
Azaro, Analía (Hospital Universitari Vall d'Hebron) ;
Bruna, Alejandra (The Institute of Cancer Research (Londres)) ;
Rodríguez, Olga (Hospital Universitari Vall d'Hebron) ;
Guzmán, Marta (Hospital Universitari Vall d'Hebron) ;
Grueso, Judit (Hospital Universitari Vall d'Hebron) ;
Viaplana, Cristina (Hospital Universitari Vall d'Hebron) ;
Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron) ;
Su, Faye (Novartis Pharmaceuticals) ;
Lin, Kui (Genentech, Inc., South San Francisco) ;
Clarke, Robert B. (Manchester Breast Centre) ;
Caldas, Carlos (Cancer Research UK) ;
Arribas, Joaquín V (Hospital Universitari Vall d'Hebron) ;
Michiels, Stefan (University Paris-Saclay) ;
García-Sanz, Alicia (Medica Scientia Innovation Research (MedSIR)) ;
Turner, Nicholas C. (The Breast Cancer Now Research Centre) ;
Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ;
Nuciforo, Paolo (Hospital Universitari Vall d'Hebron) ;
Dienstmann, Rodrigo (Hospital Universitari Vall d'Hebron) ;
Verma, Chandra S. (National University of Singapore) ;
Lopez-Bigas, Nuria (Institució Catalana de Recerca i Estudis Avançats) ;
Scaltriti, Maurizio (Memorial Sloan-Kettering Cancer Center (Nova York, Estats Units d'Amèrica)) ;
Arnedos, Monica (Inserm Unit U981 (França)) ;
Saura, Cristina (Hospital Universitari Vall d'Hebron) ;
Serra, Violeta (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. [...]
2022 - 10.1038/s41467-022-32828-6
Nature communications, Vol. 13 (september 2022)
|
|
|
9.
|
|
8 p, 641.4 KB |
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer : Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
/
Salvador Bofill, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Moreno Anton, Fernando (Hospital Clínico San Carlos (Madrid)) ;
Rodriguez Sanchez, Cesar Augusto (Hospital Universitario de Salamanca-IBSAL) ;
Galve Calvo, Elena (Hospital de Basurto (Bilbao, Biscaia)) ;
Hernando Melia, Cristina (Hospital Clínic Universitari (València)) ;
Ciruelos, Eva (Hospital Universitario 12 de Octubre (Madrid)) ;
Vidal Losada, Maria (Hospital Clínic i Provincial de Barcelona) ;
Jiménez-Rodriguez, Begoña (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
De la Cruz Merino, Luis (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Martínez Jañez, Noelia (Hospital Universitario Ramón y Cajal (Madrid)) ;
Villanueva Vazquez, Rafael (Institut Català d'Oncologia) ;
de Toro Salas, Ruben (Hospital Universitario de Jerez (Jerez de la Frontera)) ;
Anton Torres, Antonio (Hospital Universitario Miguel Servet (Saragossa)) ;
Alvarez Lopez, Isabel Manuela (Biodonostia Osasun Ikerketako Institutura (País Basc)) ;
Gavila Gregori, Joaquin (Fundació Institut Valencià d'Oncologia) ;
Quiroga Garcia, Vanesa (Institut Català d'Oncologia) ;
Vicente Rubio, Elena (Hospital Universitario Insular de Gran Canaria) ;
De la Haba-Rodriguez, Juan (Universidad de Córdoba) ;
Gonzalez-Santiago, Santiago (Hospital Universitario San Pedro de Alcántara) ;
Diaz Fernandez, Nieves (Hospital Universitario San Juan de Alicante) ;
Barnadas i Molins, Agustí (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Cantos Sanchez de Ibargüen, Blanca (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Delgado Mingorance, Juan Ignacio (Hospital Universitario Infanta Cristina) ;
Bellet Ezquerra, Meritxell (Vall d'Hebron Institut d'Oncologia) ;
de Casa, Sonia (Novartis Farmacèutica, SA) ;
Gimeno, Asuncion (Novartis Farmacèutica, SA) ;
Martin, Miguel (Hospital General Universitario Gregorio Marañón) ;
Universitat Autònoma de Barcelona
Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish women. Ribociclib in combination with endocrine therapy (ET) has shown superiority in prolonging survival in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) vs. [...]
2022 - 10.1016/j.breast.2022.09.006
Breast, Vol. 66 (september 2022) , p. 77-84
|
|
|
10.
|
|
12 p, 815.7 KB |
Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response
/
Ciriaco, Nikaoly (Hospital del Mar (Barcelona, Catalunya)) ;
Zamora, Esther (Hospital Universitari Vall d'Hebron) ;
Escrivá-de-Romaní, Santiago (Hospital Universitari Vall d'Hebron) ;
Miranda Gómez, Ignacio (Hospital Universitari Vall d'Hebron) ;
Jiménez Flores, José (Vall d'Hebron Institut d'Oncologia) ;
Saura, Cristina (Hospital Universitari Vall d'Hebron) ;
Sloane, Hillary ;
Starus, Anna ;
Fredebohm, Johannes ;
Georgieva, Lucy ;
Speight, Graham ;
Jones, Frederick ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron) ;
Espinosa-Bravo, Martín (Hospital Universitari Vall d'Hebron) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Although the standard of care is to perform surgery of primary breast cancer (BC) after neoadjuvant chemotherapy (NAC), for certain patients achieving clinical complete response (cCR) and pathologic complete response (pCR), omission of surgical treatment may be an option. [...]
2022 - 10.1177/17588359221139601
Therapeutic Advances in Medical Oncology, Vol. 14 (november 2022)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
